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ABSTRACT
Background: Several randomized phase III trials in neuroendocrine tumors (NETs) showed the clinical role
of new targeted agents and their impact on tumor response and outcome of whose patients affected by
advanced NET. In this study, we summarize the available clinical data related to clinical efficacy of targeted
therapies in the treatment of advanced NETs. Methods: A meta-analysis of randomized studies in
accordance with the PRISMA guidelines was performed after searching the databases of PubMed, the
Cochrane Library, and the ASCO University Meeting for relevant publications. Results: One thousand
9 hundred and 8 cases were included in the meta-analysis; among these, 1012 were in the experimental
arm and 896 were in the control arm. The pooled analysis of the use of target agents in NETs revealed
significantly increased of progression free survival compared to control group (hazard ratio D 0.59, 95%
CI:0.42-0.84; P D 0.003). Subgroup analysis of patients according to tumor site showed a difference in favor
of pancreatic neuroendocrine tumors. Moreover, targeted therapies improved the overall survival (hazard
ratio D 0.79, 95%CI: 0.63-0.98; P D 0.03), and response rate (hazard ratio D 3.33, 95% CI 2.02-5.49;
P < 0.00001) in all types of NETs. Conclusion: Our analysis supports the routine use of targeted agents for
treatment of neuroendocrine tumors with particular regards to the pancreatic neuroendocrine tumors.
KEYWORDS
Everolimus; bevacizumab;
NET; sunitinb
Introduction
Neuroendocrine tumors (NET) arise from cells of the endo-
crine (hormonal) and nervous systems. NETs are considered a
rare disease even their incidence appear to be increasing.1,2 The
prognosis of NETs may vary widely, depending on stage, grade
or primary tumor site.3 Surgical resection of the primary
tumors usually offer the only change of a long curative treat-
ment; however, only a low percentage of patients are candidate
to surgery as more than 50% of patients with NET have
regional or distant metastatic disease at diagnosis.3 In advanced
diseases, the therapeutic options may include: a close surveil-
lance for slowly progressive tumors; a liver-directed treatments
such as transarterial embolization; systemic treatment with
cytotoxic chemotherapy or radionuclide. However, none of
these approaches has been directly compared in randomized
clinical trials.4
In the armamentarium of systemic treatment, somatostatin
analogs, such as octrotide and lanreotide, are currently indi-
cated for the relief of symptoms in patients with functionally
active NETs.5,6 In addition, octreotide long-acting repeatable
(LAR) has significantly prolonged time to tumor progression
compared with placebo in patients with functionally active and
inactive metastatic midgut NETs,7 supporting their use as a pri-
mary approach in the NET treatment. More recently, due to a
better understanding of the biological mechanisms driving the
growth of tumor cells with neuroendocrine phenotype has led
to the development of targeted anti-cancer agents.8,9 To date, 2
agents have been approved by the US. Food and Drug Admin-
istration (FDA) for the treatment of patients with progressive,
well-differentiated pancreatic NET: sunitinib (a vascular endo-
thelial growth factor receptor-tyrosine kinase inhibitor) and
everolimus (a mammalian target of rapamycin (mTOR). Three
phase III trials demonstrated an improved in progression-free
survival (PFS) of both sunitinb and everolimus compared with
placebo,10-12 supporting their role in clinical practice.
The aim of this study is to analyze the available clinical data
from randomized controlled trials (RCTs) looking for efficacy
of target agents in patients with advanced NETs.
Materials and methods
Data retrieval strategies
We conducted the meta-analysis of randomized studies in
accordance with the PRISMA guidelines.13 The databases of
PubMed/MEDLINE, the Cochrane Library, and the American
society of clinical oncology (ASCO) Meeting were searched for
relevant publications using the following terms: “Neuroendo-
crine tumor” or “NET” or “Carcinoid tumors” and “target ther-
apy” or “sunitinib” or “everolimus” or “bevacizumab.” The
publications that were available in these databases up to
December 31, 2015, were analyzed. The search was restricted to
human studies, and the search criteria were limited to phase II
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or phase III trials. The computer search was supplemented with
manual searches of the references listed in all of the retrieved
review articles, including primary studies. When the results of a
study were reported in subsequent interim analysis, only the
most recent or complete and updated version was included in
the analysis.
Inclusion criteria
The studies were identified according to the following inclusion
criteria: 1) human participants with a NET; 2) a targeted agent
therapy alone or in combination for experimental arm; 3) the
presence of a control for comparison (placebo or not); 4) a pri-
mary outcome of response expressed as the hazard ratio (HR)
for either PFS or overall survival (OS), as well as the response
rate expressed as relative risk (RR). The following exclusion cri-
teria were used: 1) insufficient data were available to estimate
the outcomes; 2) animal studies; 3) the size of each arm was
fewer than 10 participants; and 4) the presence of a single-arm
study.
Data extraction
LZ and SV independently extracted the relevant data of each
trials, including the name of the first author, country, publica-
tion year, characteristics of the enrolled patients, median fol-
low-up and information about the study design (i.e., the type of
blinding, type of control, and methods for randomization allo-
cation), survival outcomes expressed as HRs for OS and PFS,
and the number of patients who experienced a response rate
with a grade 3-4 adverse event. The arm with the targeted agent
has been considered as the experimental. For the time-to-event
variables (OS or PFS), HRs with the 95% confidence intervals
(95%CIs) were calculated for each study. For the dichotomous
variables (partial or complete response rate and toxicity) RRs
with the 95% CIs were calculated for each study.
Quality assessment and statistical analysis
The methodological quality of each included study was assessed
by 2 independent researchers (GA and PC). The study quality
was assessed using the Jadad 5-item scale. The final score
ranged from 0 to 5.14 Disagreements were evaluated by the
kappa test, and consensus was achieved in discussion with the
corresponding author (GR).
Statistical analysis
Statistical analyses were performed using Revman 5.3. The
summary estimates were generated using a fixed-effects model
(Mantel–Haenszel method) or a random-effects model (DerSi-
monian–Laird method)15,16 depending on the absence or pres-
ence of heterogeneity. Statistical heterogeneity was assessed
using the Q-test and the I2 statistic. I2 values of 25%, 50% and
75% were considered to indicate low, moderate and high
heterogeneity, respectively.17 When P > 0.1 in the Q-test and
I2< 50%, the fixed-effects model was used; otherwise, the ran-
dom-effects model was used. Due to the small number of trials
that were included, no publication bias was assessed. A sub-
group analysis was performed to highlight any difference
between studies with different tumor sites (pancreatic NETs
versus other location). For all of the statistical analyses, a value
of P < 0.05 was regarded as statistically significant, and all of
the tests were 2-sided.
Results
Literature review, characteristics and quality of the
included studies
The search yielded 8454 potentially relevant articles. Of these,
7744 studies were excluded as duplicates. After viewing the
titles and abstracts of the 710 remaining studies, the full texts
of 21 studies were retrieved and 7 studies 10-12,18-21 with 1012
cases in experimental arm and 896 cases in the control group
were included in the meta-analysis according to the inclusion
and exclusion criteria described in the materials and methods
section (Fig. 1). One study was excluded because retracted by
the authors.22 Among these studies, 3 studies10,12,18 investigated
everolimus single agent as experimental arm, 3 studies sunitinib
and bevacizumab respectively11,19,20 and one study the combi-
nation of everolimus and bevacizumab.21 Three studies enrolled
patients with pancreatic NET10,11,21,22 only. The patients’ char-
acteristics were obtained for all studies. The characteristics of
the studies included in the meta-analysis are summarized in
Table 1. There were 2 phase II studies20,21 and 5 phase III stud-
ies.10-12,18,19 All studies had a comparator: in 310-12 the compar-
ator was placebo, while in 1 was placebo plus octreotide LAR;18
in 2 studies the comparator was pegylated (PEG)-interferon
Figure 1. Trial selection flow chart.
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alfa-2b and interferon respectively19,20 and everolimus in on
trial.21 The median Jadad score was 5, showing a good quality
of the included studies (Table 1).
Efficacy data
Data about OS and PFS were reported in Table 2. With regard
to OS, data were obtained from 4 studies.10-12,21 The pooled
analysis revealed that the new target therapies definitely
improved the OS compared with control arm (0.79, 95%CI:
0.63–0.98; P D 0.03, Fig. 2). The analysis was performed using
a fixed-effects model (I2 D 46%). In the experimental arm, a
higher PFS has been observed respect control arm for all the
included studies. All the studies reported HR for PFS, the
pooled analysis revealed an improvement with new target ther-
apies (HR D 0.59, 95% CI:0.42–0.84; P D 0.003 Fig. 3). The
random-effects model was used for the analysis of the PFSs due
to the presence of high heterogeneity (I2 D 87%) between the
trials. In the subgroups analysis of the targeted agents in pan-
creatic and non-pancreatic NET, the results revealed the tar-
geted therapies significantly improved the PFS to a greater
extent in the pancreatic NET (HR D 0.49 95%CI: 0.29–0.83)
than in non-pancreatic NET setting (HR D 0.71 95%CI: 0.49–
1.02) (Fig. 3).
Five studies reported the RR of the target agents in
NET.11,19-21 RR has been obtained in a total of 59/384 (15.3%)
patients for the experimental group and in a total of 17/383
(4.4%) patients in the control group. Using the Mantel–Haens-
zel method for combining trials, the pooled RR for achieving
an objective response with targeted agents vs. placebo or
other therapies was 3.33 (95% CI 2.02–5.49; P < 0.00001;
I2 D 0%) (Fig. 4). Regarding the toxicity, the data of the adverse
events unfortunately were not homogeneously reported in the
studies; therefore, an associated meta-analysis could not be
performed.
Discussion
Although the molecular background of sporadic NETs is
unknown, several studies suggested that the abnormal PI3K-
AKT-mTOR pathway signaling is implicated in their patho-
genesis.23 The mTOR protein is a serine-threonine kinase
regulating cell growth, proliferation, metabolism, and angio-
genesis and its autocrine activation, mediated mainly by the
Insulin-like Growth Factor 1, has been associated with neu-
roendocrine tumor cell proliferation.24 The crucial role of
mTOR pathway in NETs is also supported by the fact that
NETs pathogenesis is frequently linked with familial cancer
syndromes, such as neurofibromin 1 (NF-1) or tuberin
(TSC). In particular, the chromosome arm 16p, which con-
tains TSC-2, has been found to be lost in 37% of pancreatic
NETs.25 The phosphatase and tensin homolog (PTEN) has
been also detected mutated or deleted in the 10% up to 29%
of patients with pancreatic NETs.25 All these tumor suppres-
sor genes, if inactivated, led to an over-expression of the
mTOR pathway.26 Moreover, mTOR pathway is linked to a
progression of disease, in this context, Missiaglia et al
showed that the down-regulation of the tumor suppressor of
the Akt/mTOR pathway TSC-2 and PTEN which leads to
deregulation of the mTOR pathway are linked to progression
of pancreatic NETs to an increased rate of proliferation, and
shortened PFS and OS.25 Although the crucial role of mTOR
Table 1. Characteristics of the analyzed trials.
Study Design
Primary
endpoint
Number of Patients
Experimental Arm
Number of Patients
Control Arm
Experimental
drug Control
Tumor
location
Jaded
score
Yao 201110 III PFS 207 203 Everolimus Placebo Pancreatic 5
Raymond11 III PFS 86 85 Sunitinib Placebo Pancreatic 5
Yao 201512 III PFS 205 97 Everolimus Placebo Non-pancreatic
NETS
5
Pavel18 III PFS 216 213 Everolimus
COctreotide LAR
Placebo
C octreotide LAR
Non-pancreatic
NETS
5
Yao 2015 ASCO19 III PFS 201 201 Bevacizumab
COctereotide
Interferon
a-2BCOctereotide
Non-pancreatic
NETS
4
Yao 200820 II PFS 22 22 Bevacizumab PEG interferon
a¡2B
Non-pancreatic
NETS
3
Kulke 201521 II 75 75 75 Everolimus
CBevacizumab
Everolimus Pancreatic 3
Table 2. Data on overall survival, progression free survival, median treatment duration and median follow-up of the included studies.
OS (months) PFS (months) Median treatment Duration (months)
Study Experimental drug Control p value Experimental drug Control p value Exp Control Median Follow-up (months)
Yao 201110 NR NR 0.59 11.4 5.4 <0.001 8.79 3.74 17
Raymond11 NR NR 0.02 11.4 5.5 <0.001 4.6 3.7 NR
Yao 201512 NR NR 0.04 11 3.9 <0.0001 40.4 19.6 21
Pavel18 NR NR NR 16.4 11.3 0.026 9.25 9.15 28
Yao 2015 ASCO19 NR NR NR 16.6 15.4 0.55 NR NR NR
Yao 200820 NR NR NR 16.5 14 0.34 4.5 4.5 4.5
Kulke 201521 36.7 35 0.16 16.7 14 0.12 13 12 25.9
OS: overall survival; PFS: progression free survival; NR: not reported.
according to central assessment; Weeks; Cycles
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seems to be mainly confined in the subgroup of pancreatic
NETs (in fact about the 14% of these last present mutations
in genes in the mTOR pathway).26,27 The positive recent
data from the RADIANT-4 trial 12 based on the use of
mTOR targeting agent (everolimus) supported the leading
role of mTOR axis in NETs not only in is pancreatic but
also in lung or gastrointestinal tumors.
The angiogenesis process along with one of its “driver” such as
the vascular endothelial growth factor (VEGF) play also an impor-
tant role in NETs progression. Over expression of VEGF has been
demonstrated in pancreatic or not pancreatic NETs and it has been
associated to a worse outcome.26,28 Moreover the VEGF receptor-2
(VEGFR-2) is also generally over-expressed also in gastro-intestinal
carcinoid tumors and carcinoid cancers.26,29 Thus, targeting these
markers potentially arrest the NETs related-angiogenesis inducing,
as a consequence, a tumor downstage and an improvement in PFS/
OS.12,20,21
The present study is a systematic review and a meta-analysis of
trials to assess the efficacy of targeted agents in patients with
advanced NET. NETs are a heterogeneous disease arising from
Figure 2. Forest plots of hazard ratios (HRs) for overall survival (OS) comparing new target agents to control group. The Chi-squared test showed low heterogeneity
between the trials. The fixed effects model was used.
Figure 3. Forest plots of hazard ratios (HRs) for progression-free survival (PFS) comparing new target agents to control group. The Chi-squared test showed high hetero-
geneity between the trials. The random effects model was used.
Figure 4. Forest plots of hazard ratios (HRs) for progression-free survival (PFS) comparing new target agents to control group in the subgroup of pancreatic NETs versus
non pancreatic NETs. The Chi-squared test showed high heterogeneity between the trials. The random effects model was used.
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various primary sites such as the small intestine or other sites of the
gastrointestinal tract, and the lung,30,31 therefore their management
is complicated by a different clinical presentations, clinical disease
course, symptoms and degree of aggressiveness.3 In our analysis,
target agents improved the PFS and OS of advanced NETs patients
compared with control group. Therefore, we may confirm the
important role of targeted agents in treating the advanced NETs
and in this setting, the completion of several randomized phase III
studies has brought to the approval of 2 new sunitinib, and everoli-
mus.32 Because of the observed long survival after progression of
many patients, PFS is recommended as a feasible and relevant pri-
mary end point for both phase III studies and phase II studies,33
however we have been able to show a statistically significant
improvement also in OS for patients with NETs treated with tar-
geted therapies. In the subgroup analysis, we have reported a better
PFS in patients with pancreatic NETs versus other site of NETs
(HR D 0.49 and 0.71 respectively). However, it is well known for
chemotherapy and targeted treatment than better response is
observed for pancreatic NETs than non-pancreatic NETs. There-
fore our study empowered this issue.
The identification of the patients who will benefit or will be
resistant to targeted agents is mandatory in a clinical setting.
Unfortunately, there are less established biomarkers able to pre-
dict the response of advanced NETs to targeted agents. In the
near future, studies based on identification of biomarkers pre-
dicting response and clinical benefit to novel targeted agents in
advanced NETs patients are needed.
It is worth of notes ourmeta-analysis presents several important
limitations: 1) not all considered studies reported data on HRs of
OS, PFS and RR, 2) different drugs with different mechanism of
action have been analyzed with different impact on outcome-
related variables, 3) only one study directly compared the combina-
tion of 2 targeted therapies, however an increase in toxicity in the
combination armwas observed,21 4) this is not ameta-analysis per-
formed from individual data from randomized studies, but from
data available in literature, which is known to be much less robust,
5) data on toxicities were very heterogeneous and did not allow a
reasonable pooling of the results, 6) although, we found a good
global quality of examined studies (median Jadad score of 5), the
quality and the design of clinical studies for advanced NETs are
poor 34 due to several factors: the heterogeneity of the disease (dif-
ferent primary sites), very low incidence leading to a relative pau-
city of comparative and strategy studies. NET treatment strategy
may include several options such as surgery, through liver-targeted
therapies and several lines of systemic therapy.
Conclusions
NETs are a heterogeneous disease leading to a very difficult trial
design and algorithm of therapy. Therefore, the optimal man-
agement of advanced NETs is still a challenge for medical
oncologist. The recent success of phase III trials demonstrate
that the novel agents such as sunitinib, and everolimus are an
effective therapeutic options for patients with advanced NETs
with particular regards to the pancreatic tumors. While, the
combination of everolimus plus octreotide LAR improves PFS
in patients with advanced NETs, no data are available on the
antitumor activity of the combination of sunitinib and everoli-
mus or sunitinb octreotide and LAR. Nowadays, new pathways
with new targeted therapies are under investigation in
advanced NETs, but it is still mandatory to design and conduct
trials properly to solve the issue of the optimal management in
any subgroups of advanced NETs, maybe thankful also the
identification of “driver” biomarker for selected treatment.
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